SCHEMBL18354562

SCHEMBL18354562

COCC(COC(C)(C)C)OC

nearest known ligand 0.42

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14968999 1.00 MAPK1 (0.42) MAPK1
SCHEMBL16577200 0.92 MAPK1 (0.48) MAPK1
SCHEMBL5765880 0.83 MAPK1 (0.46) MAPK1
SCHEMBL17914141 0.83 MAPK1 (0.46) MAPK1
SCHEMBL51157 0.81
SCHEMBL24658397 0.78 MAPK1 (0.41) MAPK1
SCHEMBL14969322 0.78 MAPK1 (0.41) MAPK1
SCHEMBL18993085 0.78 MAPK1 (0.41) MAPK1
SCHEMBL18892556 0.76 MAPK1 (0.39) MAPK1
SCHEMBL19079085 0.76 PRKD3 (0.58) MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11826438-B2 Hyperbranched polyglycerol-coated particles and methods of making and using thereof YALE UNIVERSITY (US) 2023-11-28 US disclosed
US-20230355801-A1 IMMUNOTHERAPY OF SKIN CANCER USING MPLA-LOADED HPG NANOPARTICLES YALE UNIVERSITY 2023-11-09 US disclosed
US-20180177688-A1 TOPICAL FORMULATION OF HYPERBRANCHED POLYGLYCEROL-COATED PARTICLES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-06-28 US disclosed
US-20170266119-A1 HYPERBRANCHED POLYGLYCEROL-COATED PARTICLES AND METHODS OF MAKING AND USING THEREOF YALE UNIVERSITY 2017-09-21 US disclosed
US-20170000737-A1 HYPERBRANCHED POLYGLYCEROL-COATED PARTICLES AND METHODS OF MAKING AND USING THEREOF YALE UNIVERSITY 2017-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230355801-A1 IMMUNOTHERAPY OF SKIN CANCER USING MPLA-LOADED HPG NANOPARTICLES CD69, CD40LG, MPL MAPK1 2069/4885
US-11826438-B2 Hyperbranched polyglycerol-coated particles and methods of making and using thereof LIPG, CETP, LIPA MAPK1 4328/4885
US-20180177688-A1 TOPICAL FORMULATION OF HYPERBRANCHED POLYGLYCEROL-COATED PARTICLES THEREOF CUTA, KRTCAP2, HBG2 MAPK1 3908/4885
US-20170266119-A1 HYPERBRANCHED POLYGLYCEROL-COATED PARTICLES AND METHODS OF MAKING AND USING THEREOF LIPG, CETP, LIPA MAPK1 4328/4885
US-20170000737-A1 HYPERBRANCHED POLYGLYCEROL-COATED PARTICLES AND METHODS OF MAKING AND USING THEREOF LIPG, CETP, LIPA MAPK1 4328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.